Dr. David Rawitscher, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 2,116
Licensed in Texas since 1997, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: University of Texas Medical School at Houston
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
TX license K3418 (first issued 1997; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor Scott & White Medical Center Plano Plano, TX
- Baylor Scott & White the Heart Hospital Plano Plano, TX
- Baylor Scott and White Medical Center Mckinney Mc Kinney, TX
- Baylor Scott & White Medical Center - Centennial Frisco, TX
- The Heart Hospital Baylor Denton Denton, TX
Medical groups
- Healthtexas Provider Network (2,697 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 2,116
- Services billed
- 14,001
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 923 | 610 |
| Insertion of needle into vein for collection of blood sample | 620 | 429 |
| Anticoagulant management of patient taking warfarin | 572 | 270 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 515 | 412 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 494 | 206 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 465 | 384 |
| Established patient office or other outpatient visit, 20-29 minutes | 295 | 279 |
| Injection, regadenoson, 0.1 mg | 272 | 68 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 196 | 189 |
| Evaluation of lower heart chamber assist device | 189 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Plano, TX | 1,178 |
| Metoprolol Succinate Other prescribers in Plano, TX | 848 |
| Atorvastatin Calcium Other prescribers in Plano, TX | 737 |
| Carvedilol Other prescribers in Plano, TX | 583 |
| Ezetimibe Other prescribers in Plano, TX | 550 |
| Losartan Potassium Other prescribers in Plano, TX | 518 |
| Amlodipine Besylate Other prescribers in Plano, TX | 506 |
| Eliquis (apixaban) Other prescribers in Plano, TX | 481 |
| Spironolactone Other prescribers in Plano, TX | 431 |
| Jardiance (empagliflozin) Other prescribers in Plano, TX | 396 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 99 payments worth $19,057 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $11,627 |
|---|---|
| Itamar Medical Inc | $4,684 |
| Abbott Laboratories | $717 |
| Novartis Pharmaceuticals Corporation | $364 |
| Novo Nordisk Inc | $253 |
| Pfizer Inc. | $237 |
| Inspire Medical Systems, Inc. | $200 |
| AstraZeneca Pharmaceuticals LP | $189 |
| Compensation for services other than consulting (speaking, faculty) | $11,458 |
|---|---|
| Education | $4,500 |
| Food and Beverage | $3,100 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Itamar Medical Inc Oct 29, 2025 | Education WatchPATONE · Sleep Apnea testing | $4,500 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $3,317 |
| Bayer HealthCare Pharmaceuticals Inc. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $3,317 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $3,015 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $1,809 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $64,828 in research payments for these studies, mostly to the institutions running them.
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic C…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.